Addition of thiopurines can recapture response in patients with Crohn's disease who have lost response to anti-tumor necrosis factor monotherapy

Journal of Gastroenterology and Hepatology (Australia)

Volumn 28, Issue 10, 2013, Pages 1595-1599

  Ong, David E H ^a,b   Kamm, Michael A ^a   Hartono, Juanda Leo ^b   Lust, Mark ^a  

^a ST VINCENT S HOSPITAL   (Australia)

^b NATIONAL UNIVERSITY HOSPITAL   (Singapore)

Author keywords

Anti TNF; Crohn's disease; Inflammatory bowel disease; Loss of response; Thiopurine; Thiopurines

Indexed keywords

ADALIMUMAB; AZATHIOPRINE; C REACTIVE PROTEIN; INFLIXIMAB; MERCAPTOPURINE; METHOTREXATE; TUMOR NECROSIS FACTOR INHIBITOR;

ABDOMINAL CRAMP; ABDOMINAL PAIN; ADULT; ARTICLE; CLINICAL ARTICLE; COLONOSCOPY; CROHN DISEASE; DIARRHEA; DRUG SAFETY; DRUG TREATMENT FAILURE; FEMALE; HUMAN; ILEOSTOMY; LIVER TOXICITY; MALE; MONOTHERAPY; NAUSEA; PRIORITY JOURNAL; TREATMENT RESPONSE;

ANTI-TNF; CROHN'S DISEASE; INFLAMMATORY BOWEL DISEASE; LOSS OF RESPONSE; THIOPURINE; THIOPURINES;

6-MERCAPTOPURINE; ADULT; ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; CROHN DISEASE; DRUG SUBSTITUTION; DRUG SYNERGISM; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; TREATMENT FAILURE; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA; YOUNG ADULT;

EID: 84897629643     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/jgh.12263     Document Type: Article

References (26)

1. Hanauer SB, Feagan BG, Lichtenstein GR etal. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet 2002; 359: 1541-1549.
2. Kamm MA, Hanauer SB, Panaccione R etal. Adalimumab sustains steroid-free remission after 3 years of therapy for Crohn's disease. Aliment. Pharmacol. Ther. 2011; 34: 306-317.
3. Sands BE, Anderson FH, Bernstein CN etal. Infliximab maintenance therapy for fistulizing Crohn's disease. N. Engl. J. Med. 2004; 350: 876-885.
4. Hanauer SB, Sandborn WJ, Rutgeerts P etal. Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial. Gastroenterology 2006; 130: 323-333; quiz 591.
5. Sandborn WJ, Hanauer SB, Rutgeerts P etal. Adalimumab for maintenance treatment of Crohn's disease: results of the CLASSIC II trial. Gut 2007; 56: 1232-1239.
6. Colombel JF, Sandborn WJ, Rutgeerts P etal. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology 2007; 132: 52-65.
7. Gisbert JP, Panes J. Loss of response and requirement of infliximab dose intensification in Crohn's disease: a review. Am. J. Gastroenterol. 2009; 104: 760-767.
8. Baert F, Noman M, Vermeire S etal. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. N. Engl. J. Med. 2003; 348: 601-608.
9. Hanauer SB, Wagner CL, Bala M etal. Incidence and importance of antibody responses to infliximab after maintenance or episodic treatment in Crohn's disease. Clin. Gastroenterol. Hepatol. 2004; 2: 542-553.
10. Colombel JF, Sandborn WJ, Reinisch W etal. Infliximab, azathioprine, or combination therapy for Crohn's disease. N. Engl. J. Med. 2010; 362: 1383-1395.
11. Lichtenstein GR, Hanauer SB, Sandborn WJ. Management of Crohn's disease in adults. Am. J. Gastroenterol. 2009; 104: 465-483; quiz 464, 484.
12. Travis SP, Stange EF, Lemann M etal. European evidence based consensus on the diagnosis and management of Crohn's disease: current management. Gut 2006; 55 (Suppl. 1): i16-35.
13. Lichtenstein GR, Abreu MT, Cohen R etal. American Gastroenterological Association Institute technical review on corticosteroids, immunomodulators, and infliximab in inflammatory bowel disease. Gastroenterology 2006; 130: 940-987.
14. Sokol H, Seksik P, Carrat F etal. Usefulness of co-treatment with immunomodulators in patients with inflammatory bowel disease treated with scheduled infliximab maintenance therapy. Gut 2010; 59: 1363-1368.
15. Thai A, Prindiville T. Hepatosplenic T-cell lymphoma and inflammatory bowel disease. J. Crohns Colitis 2010; 4: 511-522.
16. Van Assche G, Magdelaine-Beuzelin C, D'Haens G etal. Withdrawal of immunosuppression in Crohn's disease treated with scheduled infliximab maintenance: a randomized trial. Gastroenterology 2008; 134: 1861-1868.
17. Ben-Horin S, Chowers Y. Review article: loss of response to anti-TNF treatments in Crohn's disease. Aliment. Pharmacol. Ther. 2011; 33: 987-995.
18. Sandborn WJ, Abreu MT, D'Haens G etal. Certolizumab pegol in patients with moderate to severe Crohn's disease and secondary failure to infliximab. Clin. Gastroenterol. Hepatol. 2010; 8: 688-695 e2.
19. Sandborn WJ, Rutgeerts P, Enns R etal. Adalimumab induction therapy for Crohn disease previously treated with infliximab: a randomized trial. Ann. Intern. Med. 2007; 146: 829-838.
20. Schnitzler F, Fidder H, Ferrante M etal. Long-term outcome of treatment with infliximab in 614 patients with Crohn's disease: results from a single-centre cohort. Gut 2009; 58: 492-500.
21. Xu Z, Seitz K, Fasanmade A etal. Population pharmacokinetics of infliximab in patients with ankylosing spondylitis. J. Clin. Pharmacol. 2008; 48: 681-695.
22. Vermeire S, Noman M, Van Assche G etal. Effectiveness of concomitant immunosuppressive therapy in suppressing the formation of antibodies to infliximab in Crohn's disease. Gut 2007; 56: 1226-1231.
23. Oussalah A, Chevaux JB, Fay R etal. Predictors of infliximab failure after azathioprine withdrawal in Crohn's disease treated with combination therapy. Am. J. Gastroenterol. 2010; 105: 1142-1149.
24. Ben-Horin S, Waterman M, Kopylov U etal. Addition of an immunomodulator to infliximab therapy eliminates anti-drug antibodies in serum and restores clinical response of patients with inflammatory bowel disease. Clin. Gastroenterol. Hepatol. 2013; 11: 444-447.
25. Teichgraber U, Atreya I, Atreya R etal. Infliximab treatment induces levels of the active azathioprine metabolite TGTP in Crohn's disease. Inflamm. Bowel Dis. 2013; 19: E54-55.
26. Saito S, Shimizu U, Nan Z etal. Economic impact of combination therapy with infliximab plus azathioprine for drug-refractory Crohn's disease: a cost-effectiveness analysis. J. Crohns Colitis 2013; 7: 167-174.